LABORATORIOS ABBAP PHARMA SL
Company details
- Active NIF/CIF: B72382864
-
-
-
-
Address: C/ SEVERO OCHOA, NAVE 12 - POLIGONO INDUSTRIAL REM (SANLUCAR DE BARRAMEDA) See in map
-
-
Featured products:
More information on LABORATORIOS ABBAP PHARMA SL
-
HIDALGO GARCIA DE VELASCO PABLO SAULOConsejeroAppointment: 23/10/2019
-
HIDALGO GARCIA DE VELASCO PABLO SAULOConsejero delegado mancomunadoAppointment: 23/10/2019
-
PORTILLA JIMENEZ ALFREDOConsejeroAppointment: 23/10/2019
-
PORTILLA JIMENEZ ALFREDOConsejero delegado mancomunadoAppointment: 23/10/2019
-
PORTILLA JIMENEZ ALFREDOSecretarioAppointment: 23/10/2019
-
BARES LOPEZ LYDIAConsejeroAppointment: 23/10/2019
-
BARES LOPEZ LYDIAPresidenteAppointment: 23/10/2019
Other information
The CIF assigned to LABORATORIOS ABBAP PHARMA SL is B72382864, and its commercial status is active. The company is engaged in economic activities classified under the CNAE 2042 - Fabricación de perfumes y cosméticos. Additionally, it is categorized with the SIC code -.
LABORATORIOS ABBAP PHARMA SL employs approximately Between 1 and 9 employees and records an annual turnover of less than 2 million euros. The company is registered in the Commercial Registry of Cádiz, and has 7 registration charges. The most recent announcement in Borme was published on 23/10/2019, while the last deposit of ordinary annual accounts corresponds to the year 2019.
To find out the contact information of LABORATORIOS ABBAP PHARMA SL, such as the telephone number, postal address, or website, you can access the Company Data module.
If you wish to obtain additional information about LABORATORIOS ABBAP PHARMA SL, we invite you to consult any of the available financial reports, the Annual Accounts of the company, or review the incidents of defaults registered in the RAI delinquency file.
The financial, commercial, and legal information about LABORATORIOS ABBAP PHARMA SL comes from official data sources and is automatically updated every day.
Do you want to know more about LABORATORIOS ABBAP PHARMA SL??
Find out more about this company by consulting these reports: